Park Ha Biological Technology Co Ltd

Análisis de la acción Park Ha Biological Technology Co Ltd (BYAH)

$2.190

-0.123 (-5.60%)Al cierre

Loading chart…
Máximo
2.291
Apertura
2.291
Precio medio ponderado por volumen
2.22
Volumen
4.08K
Capitalización
—
Mínimo
2.180
Importe
9.07K
EV/EBITDA, TTM
0.00

Park Ha Biological Technology Co Ltd is an investment holding company primarily engaged in developing private skincare label, direct skincare products sales and franchise alliances promotions. The Company mainly operates its business through two segments. The Products Sales segment is engaged in providing skincare and cosmetic products under the brand name Park Ha as well as offering complimentary after-sales beauty services in physical stores. The Franchise Service segment is engaged in entering franchise agreements with its franchisees, pursuant to which the franchisees are granted permission to open and operate a store under the brand name Park Ha or Geni. The Company's products include Little Blue Injection Serum, Parkha Amino Acid Cleansing Foam and other products. The Company mainly conducts its business in domestic market.

ir.parkha.cn

Análisis de IA of Park Ha Biological Technology Co Ltd (BYAH)

Mantener

While Park Ha Biological Technology Co Ltd (BYAH) has shown a recent 5-day price increase of 5.45%, its year-to-date decline of 96.59% raises significant concerns. The current price of $2.32 is far below its 200-day simple moving average of $12.405, indicating a bearish trend. The RSI is at 44.236, suggesting it is neither overbought nor oversold, but the negative forward P/E ratio of 0 and the high price-to-sales ratio of 18.10441 indicate potential valuation issues. Therefore, it may be prudent to hold off on buying until clearer positive trends emerge.

Métricas de valoración

El PER previsto actual de Park Ha Biological Technology Co Ltd (BYAH) es 0.00, frente a su media de 5 años de 0.00.

PER previsto

Muy infravalorado
Media 5A P/E
0.00
P/E actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

EV/EBITDA previsto

Muy infravalorado
Media 5A EV/EBITDA
0.00
EV/EBITDA actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Precio/ventas previsto

Muy infravalorado
Media 5A P/S
0.00
P/S actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Cronología de eventos

2026-08-05 (ET)

20:00:00

Park Ha Biological Technology Co Ltd Trading Halted, News Pending

2026-06-29 (ET)

10:30:00

Park Ha Biological Partners with Amazon for North American Market Entry

2026-06-23 (ET)

09:30:00

Park Ha Biological Establishes Strategic Partnership with Cloud Factory Technology

2026-06-12 (ET)

15:00:00

Park Ha Biological Technology Raises $2M in Direct Offering

09:00:00

Park Ha Biological Partners with Star Plus Action

Noticias

Preguntas frecuentes sobre BYAH, respondidas por Alphio AI

Park Ha Biological Technology Co Ltd is an investment holding company primarily engaged in developing private skincare label, direct skincare products sales and franchise alliances promotions. The Company mainly operates its business through two segments. The Products Sales segment is engaged in providing skincare and cosmetic products under the brand name Park Ha as well as offering complimentary after-sales beauty services in physical stores. The Franchise Service segment is engaged in entering franchise agreements with its franchisees, pursuant to which the franchisees are granted permission to open and operate a store under the brand name Park Ha or Geni. The Company's products include Little Blue Injection Serum, Parkha Amino Acid Cleansing Foam and other products. The Company mainly conducts its business in domestic market. It operates in the Consumer Non-Cyclicals sector.

While Park Ha Biological Technology Co Ltd (BYAH) has shown a recent 5-day price increase of 5.45%, its year-to-date decline of 96.59% raises significant concerns. The current price of $2.32 is far below its 200-day simple moving average of $12.405, indicating a bearish trend. The RSI is at 44.236, suggesting it is neither overbought nor oversold, but the negative forward P/E ratio of 0 and the high price-to-sales ratio of 18.10441 indicate potential valuation issues. Therefore, it may be prudent to hold off on buying until clearer positive trends emerge.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar